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SclerostinAbstract Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized
by joint inﬂammation leading to cartilage and local bone erosion. Sclerostin is a protein that in
humans has been identiﬁed as an inhibitor of the pathway and leads to decreased bone formation.
Aim of the work: This study aimed to investigate the level of serum sclerostin in RA patients, its
association with inﬂammatory proﬁle and its relation to disease activity and severity.
Patients and methods: Thirty-one Egyptian RA patients (28 females, 3 men) participated in this
study. Their median age was 40 years. Disease activity score was assessed by the disease activity
score (DAS28) and the functional status by the modiﬁed health assessment questionnaire
(MHAQ). Ten matched controls were also included. Radiological severity was assessed according
to the Larsen score. Serum sclerostin was measured.
Results: Median serum sclerostin in RA patients was 2000 ng/dl (800–3300 ng/dl) which was sig-
niﬁcantly higher than in controls [210 ng/dl (150–2859)] (Z= 4.47, p< 0.001). Sclerostin signif-
icantly negatively correlated with C-reactive protein and DAS28 (p= 0.014 and p= 0.02
respectively) and positively correlated with the Larsen score and total joint count (p= 0.03 and
p= 0.02 respectively). At serum level 267 ng/dl sclerostin has sensitivity of 96.8% to diagnose
RA and a positive predictive value of 96.6%.
Conclusion: Serum sclerostin was signiﬁcantly higher in RA patients than controls and corre-
lated with disease activity and severity which highly suggests that it may play a role in the patho-
genesis of RA making it a valuable new marker of monitoring the disease progress and prognosis.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by joint inﬂammation leading to cartilage and
local bone erosion [1]. One of the hallmarks of RA is progres-
sive bone erosion. Research on the mechanisms by which RA
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shifting the normal balance between bone formation and
resorption. The Wnt/b-catenin signaling pathway has well-
recognized roles in embryology and development, and is
emerging as a critical regulator of bone and cartilage
homeostasis in adult. Canonical Wnt signaling is initiated by
binding to frizzled receptors and co-receptors ‘LDL receptor-
related proteins 5 and 6’ (LRP5/6) which leads to b-catenin
stabilization, nuclear translocation and activation of target
genes such as Wnt-induced signaling protein-1 (WISP-1) [2].
Wnt signaling is modulated by soluble antagonists including
dickkopf-1 (Dkk1), secreted frizzled-related proteins (sFRPs),
and sclerostin (SOST).
Sclerostin is a protein encoded by the SOST gene. In
humans, it was originally believed to be a non-classical bone
morphogenetic protein (BMP) antagonist [3]. Nowadays, scle-
rostin has been identiﬁed as binding to LRP5/6 receptors and
inhibiting the Wnt signaling pathway which leads to decreased
bone formation. Sclerostin is expressed in osteocytes and some
chondrocytes and inhibits bone formation by osteoblasts [4,5].
In adult cartilage in contrast, increased Wnt–b-catenin stimu-
lates tissue breakdown rather than formation [6]. In RA bone
loss may be systemic or localized to the periarticular bone due
to arthritis of the affected joint. This process involves proin-
ﬂammatory cytokines produced by the synovial membrane,
which may increase bone resorption but also stimulate soluble
antagonists of the canonical Wnt/b-catenin signaling pathway,
including Dkk1 and sclerostin, and subsequently inhibit
osteoblast proliferation, maturation and progenitor
differentiation [7].
There is little information on changes in SOST in arthritis,
with a reduction in the number of SOST-positive osteocytes
noted in association with increased cortical bone density in
the femoral neck of patients with hip osteoarthritis (OA) [8],
and in zygapophyseal joints with OA and ankylosing spondyli-
tis [9]. Sclerostin serum concentrations depend on genetic
aspects, as well as age, sex, adiposity, kidney function and
presence of diabetes mellitus [10]. Sclerostin is not a speciﬁc
product of osteocytes, however, it is also produced by chon-
drocytes and cementocytes as well as in the liver, vascular wall
and kidney [11,12]. Previously it was reported that serum levels
of sclerostin and Dkk-1 increase in patients with juvenile
idiopathic arthritis (JIA) and tumor necrosis factor (TNF-a)
contributes to their increase [13].
The objective of this study was to investigate the level of
serum sclerostin in RA patients, its association with inﬂamma-
tory proﬁle, and its relation to disease activity and severity.
2. Patients and methods
Thirty-one RA patients (28 females, 3 males) diagnosed
according to the 2010 ACR/EULAR classiﬁcation criteria
[14] were recruited from Internal Medicine and Physical
Medicine Departments of Ain Shams University Hospitals.
The inclusion criteria in the study were an inadequate response
to one disease-modifying anti rheumatic drug and patients
were naive to anti-TNFa therapy. Ten age and sex matched
apparently healthy subjects were included as a control group.
The study was conducted in accordance with the World
Medical Association Declaration of Helsinki for human sub-
jects and the study was approved by the ethics committee ofthe Faculty of Medicine Ain Shams University, and all partic-
ipants gave us their written informed consent before
enrollment.
All patients underwent full medical history taking and clin-
ical examination with special attention to tender joint count
(TJC), swollen joint count (SJC) and morning stiffness.
Patients who had Paget disease, multiple myeloma, breast can-
cer, bone metastasis and patients who were receiving biological
treatment in the form of TNF-a inhibitors during the last
6 months were excluded from this study. Disease activity score
(DAS28) was assessed and considered low (DAS28 P2.6 
<3.2) moderate (P3.2–<5.1), high (P5.1) and DAS28
<2.6 as remission [15]. Modiﬁed Health assessment question-
naire (MHAQ) was calculated; eight activities were rated as
0 = without any difﬁculty, 1 = with some difﬁculty, 2 = with
much difﬁculty, and 3 = unable to do. MHAQ scores were
divided into categories of mild (MHAQ <1.3), moderate
(1.3 <MHAQ< 1.8) and severe (MHAQ >1.8) functional
losses [16].
Laboratory evaluation included complete blood count
(CBC), erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP) and rheumatoid factor (RF). Plain X-ray of the
hands (10 MCPs) and wrists was assessed according to the
Larsen method (scoring from 0 to 60) [17]. Serum level of scle-
rostin was measured using sandwich enzyme immunoassay
(ELISA) technique (BIOMEDICA GRUPPE). The procedure
was done according to the manufacturer instruction as
supplied with in the kit for both patients and controls. 20 ll
standard/sample/control was added into appropriate wells fol-
lowed by 50 ll AB (biotinylated anti Sclerostin antibody) then
the wells were covered and incubated overnight (18–24h) at
room temperature (18–24C) in the dark. Washing for 5 times
was performed followed by adding 200 ll conjugate and
incubated for 1hour at room temperature in the dark. After
washing was performed 200 ll substrate was added and
incubated for 30 min at room temperature in the dark. 50 ll
stop solution was added and the absorbance was measured
at 450 nm with reference 630 nm.
2.1. Statistical methods
IBM SPSS statistics (V. 22.0, IBM Corp., USA, 2013) was
used for data analysis. Data were expressed as mean ± SD
for quantitative parametric measures in addition to median
and percentiles for quantitative non-parametric measures.
The following tests were done: Comparison between two inde-
pendent groups for non-parametric data using Wilcoxon
Rank Sum test; Comparison between more than 2 patient
groups for non-parametric data using Kruskal–Wallis test;
Ranked Spearman correlation test to study the possible
association between each two variables among each group
for non-parametric data. The probability of error at 0.05
was considered signiﬁcant while at 0.01 and 0.001 are highly
signiﬁcant. The ROC curve (receiver operating characteristic)
was used to evaluate the sensitivity and speciﬁcity of serum
sclerostin in diagnosis of the patients.
3. Results
This study included 31 RA patients (28 females, 3 males). The
clinical characteristics, laboratory and radiological ﬁndings,
Table 1 Clinical features, laboratory and radiological ﬁndings
in rheumatoid arthritis patients.
Data Rheumatoid arthritis patients
(n= 31)
Median
[percentile 25th–75th]
Range
Agea (years) 40 [26–48] (23–58)
Disease durationa (month) 36 [12–60] (1–240)
Pain VASa (mm) 6 [3–7] (1–8)
TJCa 5 [2–9] (0–19)
ESRa (mm/h) 45 [30–60] (10–120)
CRPa (mg/dl) 25 [12–90] (5–128)
Hbb (g/dl) 11.01 ± 1.45 (8.1–13.2)
MCVb 85.11 ± 7.52 (72–109.8)
Plateletsb (·103/mm3) 260.6 ± 58.6 (200–398)
Neutrophils% 75 [50–70] (7.9–86.2)
Lymphocytes% 33 [25–39.6] (0.7–44.8)
DAS28 4.9 [4–5.5] (2.5–6.1)
MHAQb 0.46 ± 0.42 (0–1.8)
Larsen score 2 [0–20] (0–25)
Serum sclerostin (ng/dl) 2000 [800–3300] (256–5500)
VAS: visual analog scale, TJC: tender joint count, ESR: Erythro-
cyte sedimentation rate, CRP: C-reactive protein, Hb: hemoglobin,
MCV: mean corpuscular volume, DAS28: Disease activity score in
28 joints, MHCQ: modiﬁed health assessment questionnaire.
Results are presented as mediana [25th–75th percentile] or as
mean ± SDb. Range is presented as (min–max).
Table 3 Correlation between serum sclerostin levels and
clinical, laboratory and radiological parameters in RA patients.
Variable R (p) RA patients (n= 31) sclerostin level
Age 0.19 (0.35)
Disease duration 0.01 (0.96)
Pain VAS 0.36 (0.07)
TJC 0.52 (0.02)
ESR (mm/h) 0.29 (0.16)
CRP (mg/dl) 0.53 (0.01)
Hb (g/dl) 0.14 (0.49)
MCV 0.15 (0.45)
Platelets (·103/mm3) 0.19 (0.34)
WBC (·103/mm3) 0.1 (0.63)
DAS28 0.47 (0.02)
MHAQ 0.36 (0.07)
Larsen score 0.43 (0.03)
VAS: visual analog scale, TJC: tender joint count, ESR: erythrocyte
sedimentation rate, CRP: C-reactive protein, Hb: hemoglobin,
MCV: mean corpuscular volume, WBC: white blood cell, DAS28:
disease activity score in 28 joints, MHAQ: modiﬁed health assess-
ment questionnaire. Values in bold denote a signiﬁcant result at
p< 0.05.
Table 4 Comparison of serum sclerostin among the sub-
groups of RA patients according to DAS28.
Disease activity
DAS28
Serum sclerostin (ng/dl) in RA patients (n= 31)
Median
[25–75th percentile]
Range H p
Low 1200 [0–800] (800–2000) 1.55 0.24
Moderate 2050 [900–3300] (500–3200)
High 3150 [500–3300] (1056–5500)
This table showed non signiﬁcant relation between the 3 subgroups
of RA patients.
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10 controls were 9 females and 1 male with a median age of
37 years (ranging from 24 to 55 years). Four RA patients
had swollen joints (mostly MCPs and wrists). DAS28 was high
in 13 (41.9%), moderate in 15 (48.3%) and low in 1 patient.
Among 31 RA patients, 13 patients (41.9%) had different
forms of extra-articular manifestations in the form of subcuta-
neous nodules, Raynaud’s phenomena, dry eye, dry mouth and
myalgia. In RA patients, the ESR was elevated in 29 (93.5%)
and the CRP in 18 patients (58%). Twenty-nine (93.5%)
patients had a positive RF, 3 (9.6%) had leukocytosis, 3
(9.6%) had leucopenia and 9 (30%) had anemia. Twenty
(64.5%) patients had a MHAQ more than 1.8 reﬂecting severe
disease.
Comparison between serum sclerostin level in patients and
controls is expressed in Table 2. Among RA patients, median
serum sclerostin level in females (28) was 2800 (800–
3300) ng/ml, while in 3 males was 2000 (2000–1200) ng/ml,
with no signiﬁcant difference between both groups
(Z= 0.47, pP 0.05). Correlation of sclerostin to clinical,
laboratory and radiological parameters is shown in Table 3
and to the disease activity in Table 4. When comparing serum
sclerostin levels between low and high DAS28 scores, aTable 2 Serum sclerostin in rheumatoid arthritis patients and
controls.
Median (percentile 25th–75th) Z p
Patients 2000 (800–3300) 4.47 <0.001
Controls 210 (149.8–2858.8)signiﬁcant relation exists (Z= 3.47, p= 0.01), which reﬂects
that sclerostin level was affected by disease activity. At serum
level of 267 ng/dl, sclerostin has a sensitivity of 96.8% to diag-
nose active RA (Table 5, Fig. 1).
4. Discussion
Rheumatoid arthritis (RA) is a chronic autoimmune inﬂam-
matory disease that primarily attacks synovial joints, leading
to articular destruction and functional disability [18,19].
Progressive joint destruction is a hallmark of the disease and
results from both increased bone resorption and the lack of
repair mechanisms. Sclerostin is a potent inhibitor of osteo-
blast development by antagonizing the Wnt/b-catenin signal-
ing pathway [20]. This study was conducted to determine the
role of sclerostin in the pathogenesis of RA and its relation
to disease activity and severity.
Serum sclerostin level was signiﬁcantly high in current RA
patients compared to the control (p< 0.001) and signiﬁcantly
increased with higher disease activities. These results were con-
sistent with the study done by Vis et al. [21] who reported a sta-
tistically signiﬁcant increase in RA patients with a similar
Table 5 Sensitivity and speciﬁcity of serum sclerostin in RA patients.
Serum sclerostin Test of accuracy Sensitivity Speciﬁcity Predictive value
Positive Negative
At titer 267 ng/dl 95.1% 96.8% 66.7% 96.6% 90%
This table showed a (96.8%) sensitivity of sclerostin to diagnose active RA.
Figure 1 ROC curve analysis showing the diagnostic perfor-
mance of sclerostin for discriminating RA patients from control.
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ing to the gender (p> 0.05).
A signiﬁcant correlation was found between the serum scle-
rostin level and the radiographic damage as assessed by the
Larsen score and this was in harmony with another study
[21] that reported the radiological score according to Sharp
van der Heijde.
Sclerostin showed a highly signiﬁcant negative correlation
with CRP (r= 0.53, p 6 0.01) and DAS28 (r= 0.47,
p< 0.5) and signiﬁcantly positive correlated with TJC
(r= 0.52, p< 0.05) and Larsen score (r= 0.43, p< 0.05).
This was comparable to a previous study by Hashimoto et al.
[22] who reported that serum sclerostin negatively correlated
with CRP and Hb level. On the other hand, Eissa el al., [23],
reported no statistically signiﬁcant correlation with radiological
grading which could be attributed to the longer disease duration
of their patients as most radiological changes and bone destruc-
tion occur in the ﬁrst 2 years, also it may be due to different radi-
ological scores chosen in their study.Moreover, in agreement to
the present study, Vis et al. [21] and Lim et al. [24] demonstrated
that sclerostin signiﬁcantly negatively correlated with DAS28.
Moreover, Brabnikova-Maresova and coworkers reported a sig-
niﬁcant correlation between the number of tender joints and
serum sclerostin in adult patients with JIA [13]. This could be
explained by a hypothesis suggesting that chondrocytes and cells
of the subchondral bonemay contribute to circulating sclerostin
in blood.
In the present work, sclerostin was not correlated with age,
disease duration and blood cells or Hb level; this could be
explained by the small size sample of RA patients with rela-
tively short disease duration and their normal complete blood
count. However, there was a tendency for a negative correla-
tion between serum sclerostin and Hb levels.
It was found in our study that at serum level 267 ng/dl scle-
rostin has a sensitivity of 96.8% to diagnose active RA withpositive predictive value of 96.6% which makes it a valuable
new marker to monitor disease activity of RA. The small num-
ber of the patients and control, and cross sectional design of
the study are among the limitations of the present work.
In conclusion the present results imply that sclerostin may
play a role in the pathogenesis of RA and may be a useful
index for monitoring this disease. Further larger longitudinal
studies are necessary to investigate the pathogenic role of scle-
rostin in disease progression and the possibility to antagonize
its effect as a therapeutic intervention.
Conﬂict of interest
None.
Acknowledgement
We are appreciating the effort and cooperation by Dr. Ahmed
Kamal, chemical and clinical pathology for adding to this wor-
thy work by accomplishing the statistical package of results.
References
[1] Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic
diseases: the effects of inﬂammation on bone. Immunol Rev
2005;208:228–51.
[2] Blom AB, van Lent PL, van der Kraan PM, van den Berg WB. To
seek shelter from the WNT in osteoarthritis? WNT-signaling as a
target for osteoarthritis therapy. Curr Drug Targets 2010;11:
620–9.
[3] Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T,
Skonier JE, et al. Osteocyte control of bone formation via
sclerostin, a novel BMP antagonist. EMBO J 2003;22(23):
6267–76.
[4] Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S,
et al. Bone density ligand, Sclerostin, directly interacts with LRP5
but not LRP5G171V to modulate Wnt activity. J Bone Miner Res
2006;21(11):1738–49.
[5] Burgers TA, Williams BO. Regulation of Wnt/b-catenin signaling
within and from osteocytes. Bone 2013;54(2):244–9.
[6] Voorzanger-Rousselot N, Ben-Tabassi NC, Garnero P. Opposite
relationships between circulating Dkk-1 and cartilage breakdown
in patients with rheumatoid arthritis and knee osteoarthritis. Ann
Rheum Dis 2009;68:1513–4.
[7] Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, et al. Circulating
Dickkopf-1 is correlated with bone erosion and inﬂammation in
rheumatoid arthritis. J Rheumatol 2011;38:821–7.
[8] Power J, Poole KE, van Bezooijen R, Doube M, Caballero-Alias
AM, Lowik C, et al. Sclerostin and the regulation of bone
formation: effects in hip osteoarthritis and femoral neck fracture.
J Bone Miner Res 2010;25:1867–76.
[9] Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M,
Mueller R, et al. Altered skeletal expression of sclerostin and its
link to radiographic progression in ankylosing spondylitis.
Arthritis Rheum 2009;60:3257–62.
Sclerostin as an innovative insight towards understanding Rheumatoid Arthritis 75[10] Kuipers A, Zhang Y, Yu S, Kammerer M, Nestlerode S, Chu Y,
et al. Relative inﬂuence of heritability, environment and genetics
on serum sclerostin. Osteoporos Int 2014;25:905–12.
[11] Chan B, Fuller E, Russell A, Smith S, Smith M, Jackson T, et al.
Increased chondrocyte sclerostin may protect against cartilage
degradation in osteoarthritis. Osteoarthritis Cartilage
2011;19:874–85.
[12] Rhee Y, Kim J, Han J, Lim SK, Kim S. Effect of liver dysfunction
on circulating sclerostin. J Bone Miner Metab 2014;32:545–9.
[13] Brabnikova-Maresova K, Jarosova K, Pavelka K, Stepan J.
Serum sclerostin in high-activity adult patients with juvenile
idiopathic arthritis. Arthritis Res Ther 2014;16:46.
[14] Aletaha D, Neogi T, Silman AJ, Felson DT, Bingham III CO,
Birnbaum NS, et al. Rheumatoid arthritis classiﬁcation criteria:
an American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:
1580–8.
[15] Prevoo MLL, Hof van’t MA, Kuper HH, Leeuwen van MA,
Putte van de LBA, Riel van PLCM. Modiﬁed disease activity
scores that include twenty-eight-joint counts: development and
validation in a prospective longitudinal study of patients with
rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
[16] Pincus T, Summey JA, Soraci Jr SA, Wallston KA, Hummon NP.
Assessment of patient satisfaction in activities of daily living using
a modiﬁed Stanford Health Assessment Questionnaire. Arthritis
Rheum 1983;26(11):1346–53.[17] Larsen A, Dale K, Eek M. Radiographic evaluation of rheuma-
toid arthritis and related conditions by standard reference ﬁlms.
Acta Radiol Diagn (Stockh) 1977;18:481–91.
[18] Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of
synovial inﬂammation. Int J Biochem Cell Biol 2004;36:372–8.
[19] Firestein GS. Evolving concepts of rheumatoid arthritis. Nature
2003;423:356–61.
[20] Wehmeyer C, Stratis A, Kramer I, Kneissel M, Pap T, Dankbar
B. Loss of the Wnt inhibitor sclerostin promotes pannus forma-
tion and accelerates joint destruction in the hTNFtg mouse model
of rheumatoid arthritis. Ann Rheum Dis 2011;70:A74.
[21] Vis M, Britsemmer K, Heijboer AC, Bravenboer N, Van
Schaardenburg D, Lems WF. Sclerostin levels in rheumatoid
arthritis and its relationship to disease activity and radiographic
joint damage. Arthritis Rheum 2011;63(Suppl. 10):1799 [abstract].
[22] Hashimoto J, Hirao M, Shi K, Ebina K, Kaneshiro S, Nampei A,
et al. Serum sclerostin and Dkk-1 in patients with rheumatoid
arthritis. Ann Rheum Dis 2012;71(Suppl. 3):644.
[23] Eissa M, Anwar S, Fakhreldin S, Mehaney D. Serum sclerostin
level among Egyptian rheumatoid arthritis patients: relation to
bone mineral density, disease activity and radiological grading.
Ann Rheum Dis 2014;73(Suppl. 2):893–4.
[24] Lim MJ, Kwon SR, Joo K, Son MJ, Park SG, Park W. Early
effects of tumor necrosis factor inhibition on bone homeostasis
after soluble tumor necrosis factor receptor use. Korean J Intern
Med 2014;29(6):807–13.
